PROCEPT BioRobotics Corporation

NasdaqGM:PRCT Stock Report

Market Cap: US$3.2b

PROCEPT BioRobotics Past Earnings Performance

Past criteria checks 0/6

PROCEPT BioRobotics's earnings have been declining at an average annual rate of -16.5%, while the Medical Equipment industry saw earnings growing at 14.9% annually. Revenues have been growing at an average rate of 53.8% per year.

Key information

-16.47%

Earnings growth rate

56.13%

EPS growth rate

Medical Equipment Industry Growth8.90%
Revenue growth rate53.83%
Return on equity-23.18%
Net Margin-36.20%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

PROCEPT BioRobotics: A 'Razor And Razor Blade' Business Model

May 19

US$77.00: That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After Its Latest Results

Apr 27
US$77.00: That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After Its Latest Results

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects

Apr 18
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects
author-image

HYDROS Robotic System Launch And Aquablation Trials Will Drive Future Market Expansion

Launch of HYDROS Robotic System and FDA approvals likely to increase procedural adoption and drive revenue growth.

Procept BioRobotics: Strong Growth, But Profitability Seems Far Away

Mar 11

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$93.86 Price Target

Feb 28
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$93.86 Price Target

What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S

Dec 05
What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S

Procept BioRobotics: Continued Growth Runway Ahead

Nov 26

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31
Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Sep 12

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 27

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Aug 25
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04
Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05
The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07
Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14
Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27
Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Revenue & Expenses Breakdown

How PROCEPT BioRobotics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:PRCT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 25249-9018766
31 Dec 24224-9117162
30 Sep 24200-10015962
30 Jun 24177-10415057
31 Mar 24156-10314151
31 Dec 23136-10613248
30 Sep 23116-10712144
30 Jun 23102-10511340
31 Mar 2385-9810135
31 Dec 2275-878929
30 Sep 2261-777924
30 Jun 2250-696622
31 Mar 2241-645919
31 Dec 2134-605119
30 Sep 2128-574418
30 Jun 2121-553917
31 Mar 2114-533417
31 Dec 208-533016
31 Dec 196-422913

Quality Earnings: PRCT is currently unprofitable.

Growing Profit Margin: PRCT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PRCT is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.

Accelerating Growth: Unable to compare PRCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRCT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.5%).


Return on Equity

High ROE: PRCT has a negative Return on Equity (-23.18%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 18:04
End of Day Share Price 2025/05/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PROCEPT BioRobotics Corporation is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Craig BijouBofA Global Research
Neil ChatterjiB. Riley Securities, Inc.
Michael GormanBTIG